Cabaletta Bio Inc. is a biotechnology company that specializes in developing transformative therapies for patients with B cell-mediated autoimmune diseases. Headquartered in Philadelphia, Pennsylvania, the company was founded in 2017 with a focus on advancing cutting-edge cellular therapies to address unmet medical needs.
At the core of Cabaletta Bio's mission is its innovative approach to treating autoimmune diseases through precision medicine. The company is known for its proprietary technology platform, T cell antigen coupler (TAC), which allows for the creation of personalized cell therapies. These therapies are designed to target and eliminate disease-causing B cells while sparing healthy cells, offering a potentially safer and more effective treatment option.
Cabaletta Bio's primary focus lies in the development of its lead product candidate, DSG3-CAART, which targets patients with mucosal pemphigus vulgaris, a rare autoimmune disease. The company's commitment to advancing this therapy showcases its dedication to addressing unmet medical needs and revolutionizing autoimmune disease treatment.
The company's collaborations and partnerships within the biotechnology and pharmaceutical industries are a testament to its credibility and potential. Cabaletta Bio's focus on research and development, combined with its innovative approach, positions it at the forefront of efforts to redefine treatment paradigms for autoimmune diseases.
Cabaletta Bio's vision is to leverage its TAC platform to develop a pipeline of therapies for various autoimmune diseases, providing hope for patients who often have limited treatment options. With its strong scientific foundation, innovative technology, and commitment to revolutionizing autoimmune disease treatment, Cabaletta Bio remains a significant player in the biotechnology landscape, contributing to the advancement of precision medicine and patient care.